CALT News and Press, Calliditas Therapeutics AB From 05/18/22

Calliditas Therapeutics press release (NASDAQ:CALT): Q1 GAAP EPS of -SEK 3.95. Revenue of SEK 49.7M. Cash amounted to SEK 825.4M and SEK 867.3M as of March 31, 2022 and 2021, respectively. For further details see: Calliditas Therapeutics GAAP EPS of -SEK 3.95, revenue of SEK 49.7M

Calliditas Therapeutics: Interim Report Q1, 2022 PR Newswire STOCKHOLM , May 18, 2022 /PRNewswire/ -- Start of TARPEYO™ Commercial Launch in the US "During the first quarter Calliditas launched its first commercial product, TARPEYO, in the ...

First patient randomized in Phase 2 trial in head and neck cancer PR Newswire STOCKHOLM , May 17, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") today announced that the first patient has been ran...

Calliditas Therapeutics (NASDAQ:CALT) announces the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chronic autoimmune disease. IgANConnect.com provides individuals diagnosed with IgA nephropathy and caregivers the tool...

STOCKHOLM, Sweden, May 14, 2022 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced the launch of IgAN Connect, a new online platform to provide resources to people living with IgA nephropathy, or IgAN, a chro...

Calliditas Therapeutics to participate in upcoming investor conferences PR Newswire STOCKHOLM , May 10, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") today announced that its management te...

Calliditas Therapeutics' 2021 Annual Report Published PR Newswire STOCKHOLM , April 27, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) today announces that the Annual Report for 2021 now is available at the company's websi...

Travere Therapeutics (TVTX) is a US-based pharmaceutical company with a lead asset Sparsentan that targets rare kidney diseases (IgAN and FSGS). We do not think the FDA will approve Sparsentan due to the drug's inability to drive material eGFR benefit even though it demonstrated subst...

Calliditas CEO acquires shares through the exercise of Calliditas' warrant program 2018/2022 PR Newswire STOCKHOLM , March 24, 2022 /PRNewswire/ -- Calliditas Therapeutics AB (publ) (Nasdaq: CALT, Nasdaq Stockholm: CALTX) ("Calliditas") announced today that CEO...

FLORHAM PARK, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced the appointment of Molly Henderson t...